Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Donor Virus-Specific CMV or AdV in Treating CMV or AdV Reactivation or Disease in Patients who have Undergone Stem Cell Transplant or Solid Organ Transplant

Trial Status: temporarily closed to accrual

This phase I trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in patients who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill viral cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.